iShares JPMorgan USD Emerging Markets Bond ETF vs Philip Morris International Inc. — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.63, while Philip Morris International Inc. trades at $180.66 (market cap $281.91B). The key difference: Philip Morris International Inc. pays a 3.25% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and Philip Morris International Inc. is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | PM | |
|---|---|---|
Sector | Fixed Income | Consumer Staples |
52-Week High | $97.74 | $191.86 |
52-Week Low | $91.59 | $144.33 |
Market Cap | — | $281.91B |
Enterprise Value | — | $328.41B |
Dividend Yield | — | 3.25% |
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.625 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF has demonstrated stable dividend distributions with recent payouts around $0.40-0.41 per share. Emerging market bond ETFs face increased institutional interest but remain sensitive to Federal Reserve policy and geopolitical risks.
The outlook for EMB hinges on emerging market sovereign debt performance amid shifting Fed rates and global risk appetite. Key opportunities include attractive yields relative to developed markets, while risks center on currency volatility and sovereign default exposure in hard currency bonds. Current technical weakness suggests cautious near-term positioning.
No Aura AI signal available yet.
Trailing returns across standard periods
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →